Abstract:e12625 Background: Individual tumors of breast cancer patients possess unique characteristics that may influence their neoadjuvant therapy (NAT) response to specific cytotoxic agents and treatment choices. Therefore, it is essential to have a platform that can assist in the personalized selection of chemotherapy for individual patients. Previously, we reported an in vitro model called patient-derived tumor-like cell clusters (PTC), which can structurally and functionally recapitulate original tumors. Retrospective research has shown that PTC hold potential as reliable pre-clinical drug testing model for guiding NAT therapeutic options in early breast cancer patients. Methods: This prospective, phase II, open-label study aimed to validate the efficacy of drug screening on patient-derived tumor-like cell clusters (PTCs). TNBC and HER2 positive patients received neoadjuvant therapy based on subtype and personalized drug testing on PTCs. TNBC patients were treated based on drug testing, receiving either TA (taxanes combined with anthracyclines) or TP (taxanes combined with carboplatin). HER2 positive patients received treatment based on drug testing, including THP (taxanes, trastuzumab and pertuzumab) or TCbHP (taxanes, carboplatin, trastuzumab, and pertuzumab). Sample size calculation was performed using Fleming's two-stage design. For TNBC patients, if 10 or more out of 20 patients achieved pCR in the first stage, an additional 26 patients would be enrolled in the second stage. For HER2-positive patients, the sample size was same with TNBC patients. The study was approved by the Ethics Committee of Peking University People's Hospital in Beijing and was registered on ClinicalTrials.gov (NCT04750122, NCT04836156). This time, we report the results of the first stage. Results: Among 20 enrolled TNBC patients in the first stage, 15 achieved pCR with the rate of 75%. 17 patients (85%) had RCB 0-I score while 3 patients (15%) had an RCB-II score. 14 patients received TP as it demonstrated greater sensitivity in vitro. Out of these 14 patients, 10 patients (71.4%) achieved pCR. Six patients received TA as it was more effective in drug testing. Among these patients, 5 (83.3%) patients achieved pCR. Out of 20 enrolled HER2-positive patients, 16 achieved pCR, resulting in a pCR rate of 80%. Six patients received THP treatment based on their sensitivity to this regimen in drug testing. Among these patients, 5 (83.3%) achieved a pCR. 14 patients who were sensitive to TCbHP but not to THP in drug testing received TCbHP treatment. Among these patients, 11 (78.6%) achieved pCR. The non-pCR patients had 2 RCB-II score and the ORR was 100% for all 14 patients. Conclusions: Our results demonstrate that personalized drug testing on PTCs can effectively guide the choice of neoadjuvant therapy for early TNBC and HER2-positive breast cancer patients. Clinical trial information: NCT04750122 , NCT04836156 .

HER2 and PTEN as Predictive Markers for Breast Cancer Neoadjuvant Chemotherapy with Anthracycline Plus Paclitaxel

HER2 Protein Expression Level is Positively Associated with the Efficacy of Neoadjuvant Systemic Therapy in HER2-positive Breast Cancer

HER2 as a predictive factor for successful neoadjuvant anthracycline chemotherapy of locally advanced and early breast cancer

HER2 and Response to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer

Her2 and Topoisomerase Ii Alpha: Possible Predictors of Response to Neoadjuvant Chemotherapy for Breast Cancer Patients

Ppar Signaling Pathway May Be an Important Predictor of Breast Cancer Response to Neoadjuvant Chemotherapy

Efficacy and Safety of Neoadjuvant Therapy for HER2-positive Early Breast Cancer: a Network Meta-Analysis

Estrogen Receptor-Related Genes As An Important Panel Of Predictors For Breast Cancer Response To Neoadjuvant Chemotherapy

TOPⅡa amplification predicts response of anthracycline - based neoadjuvant chemother-apy in HER2 positive breast cancer

Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer - a single center experience

Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade

Clinical significance of quantitative gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting.

Protein profiling predicts the response to anthracycline and taxanes based neo-adjuvant chemotherapy in breast cancer

Prognostic and Predictive Value of Phospho-p44/42 and Pakt in HER2-positive Locally Advanced Breast Cancer Patients Treated with Anthracycline-Based Neoadjuvant Chemotherapy

Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer

Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer

Relationship Between Tumor Markers, ER/PR, HER2, Ki67 and CyclinA2 and Clinical Efficacy of Neoadjuvant Chemotherapy

Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 were associated with chemosensitivity for breast cancers.

A Prospective Phase II Study of Neoadjuvant Therapy Guided by Personalized Drug-Testing on Patient-Derived Tumor-Like Cell Clusters for Early Breast Cancer.

The Potential Biomarkers in Predicting Pathologic Response of Breast Cancer to Three Different Chemotherapy Regimens: a Case Control Study

Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer